Quick Answer
SpyGlass Pharma, Inc. reported Net Income of -$39.87 million for fiscal year 2025.
SpyGlass Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$39.87M -36.7% |
-$29.16M | — |
| Diluted EPS | -$17.98 -10.2% |
-$16.31 | — |
| Total Assets | $115.87M +396.9% |
$23.32M | — |
| Cash and Equivalents | $96.36M +492.3% |
$16.27M | — |
| Stockholders Equity | -$98.84M -63.4% |
-$60.47M -83.3% |
-$32.98M |
| R&D Expense | $29.18M +46.0% |
$19.98M | — |
| Operating Income | -$41.45M -53.2% |
-$27.06M | — |
| Shares Outstanding | 2.20M +0.3% |
2.20M | — |
- SpyGlass Pharma, Inc. reported Net Income of -$39.87 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed a decrease of -36.7% in Net Income compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Diluted EPS of $17.98 per share (loss) for fiscal year 2025.
- SpyGlass Pharma, Inc. showed a decrease of -10.2% in Diluted EPS compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Total Assets of $115.87 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed an increase of +396.9% in Total Assets compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Cash and Equivalents of $96.36 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed an increase of +492.3% in Cash and Equivalents compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Stockholders Equity of -$98.84 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed a decrease of -63.4% in Stockholders Equity compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported R&D Expense of $29.18 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed an increase of +46.0% in R&D Expense compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Operating Income of -$41.45 million for fiscal year 2025.
- SpyGlass Pharma, Inc. showed a decrease of -53.2% in Operating Income compared to the prior fiscal year.
- SpyGlass Pharma, Inc. reported Shares Outstanding of 2.20 million shares for fiscal year 2025.
- SpyGlass Pharma, Inc. showed an increase of +0.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: